Daiichi Sankyo Announces Reorganization of its Research & Development Structure

For Immediate Release

2015.12.01

Daiichi Sankyo Announces Reorganization of its Research & Development Structure

Tokyo, Japan (December 1, 2015) - Daiichi Sankyo Company, Limited (Chuo-Ku, Tokyo; hereinafter, Daiichi Sankyo) today announced its decision to close its research subsidiary, U3 Pharma GmbH (Martinsried, Germany; hereinafter, U3).

Daiichi Sankyo intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the global R&D capacities have been reviewed and the Company has decided to concentrate core research functions of Daiichi Sankyo Group in future.

U3, with about 40 employees and which is engaged in research and development work on antibody targeting for cancer treatments, will transfer its current research and development tasks to the Biologics Function in Tokyo.

Daiichi Sankyo will provide a more detailed update on the impact of this announcement on its FY2015 business results at a later date.

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Suggested Articles

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.